Debevoise & Plimpton LLP is advising J.P. Morgan as financial advisor to Olink Holding AB (Nasdaq: OLK) in its sale to Thermo Fisher Scientific (NYSE: TMO), valuing Olink at $3.1 billion. For more information, please see the company’s press release.

Olink is a Sweden-based company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients.

The Debevoise team is led by M&A partner Andrew Bab and includes law clerk Ilya Balabanovsky.